We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions regarding Oxford Biomedica (OXB) are heating up, fueled by recent financial projections that suggest mid- to high-single digit net sales growth and an anticipated EBITDA margin of over 20% in 2025. Participants expressed optimism about the company's growth trajectory, as one investor stated, “With the momentum we are seeing in the business, we expect to continue our strong sales growth with margin expansion in 2025.” Moreover, there are hopeful sentiments around a potential trading update expected in February, further stirring interest among investors.
However, concerns about communication from OXB's management remain a common thread in discussions. Discussions often emphasize the need for clearer guidance from the company, with comments like, “...we need to know what OXB are up to and they plainly either can't tell us or don't want to,” reflecting a degree of frustration. Market movements have recently shown volatility, with optimistic predictions about significant price breakouts, yet participants cautioned against potential anomalies in trading patterns. As one commentator aptly noted, there is a pervasive sentiment that, “...whoever or whatever has been keeping a lid on the price for a long time...could be aware that a trading update is definitely coming.” Overall, while investor sentiment is broadly positive, the call for transparency and clarity from management indicates that many are navigating this optimism with cautious scrutiny.
Show more
In recent developments, Oxford Biomedica PLC (OXB) has applied for a block listing of 500,000 ordinary shares with the Financial Conduct Authority and the London Stock Exchange. This block listing includes 300,000 shares associated with the company's Long Term Incentive Plan (LTIP) and 200,000 for the Deferred Bonus Plan (DBP). This initiative is part of OXB’s strategy to enhance its capital structure, facilitating potential future growth within the cell and gene therapy sector.
Additionally, significant shareholder notifications have emerged, with entities such as Briarwood Chase Management LLC and BlackRock, Inc. crossing thresholds in terms of voting rights in the company. Reports indicate that as of December 31, 2024, OXB's total issued share capital was 105,961,906 ordinary shares, marking no shares held in treasury. This information is critical for shareholders to assess their interest in the company and comply with relevant regulatory frameworks. Overall, these updates reflect Oxford Biomedica's commitment to enhancing stakeholder engagement while navigating its growth trajectory in a dynamic industry.
Show more
This is one of the most divisive elections in US history.The WSJ comments today- 'Among Harris's voters, 57% said they would feel "frightened" if Trump is elected, while 47% of Trump voters said they would feel frightened if Harris wins.'Whoever wins,the atmosphere is going to feel very raw. |
H, maybe you mis enterpreted my post. Donald simply has to win this one. Any other result would be simply catastrophic. It is that important. |
Sorry posted twice . |
All you need is love. All we need is NEWS, and lots of it. |
jez, |
My pound would be on redemptions super. In the runup to the budget a lot of people were selling assets out of fear. If redemptions from Liontrust took them below their minimum cash float then they would have no option but to sell holdings, and when they did that last year they simply sold the same tiny percentage of everything they held in the fund. |
Looks to me like Liontrust simply wanted to go under the 5% boundary, but why that's significant for them I've no idea. |
I think a lot of these websites just want traffic - i.e. they don't care if you follow the latest computer generated tip or not - they just want people who follow popular shares to click to look at the latest tip so that the website owner gets a penny from each of the advertisers on the page. Enough traffic and it must be quite lucrative else they wouldn't be able to pay Google monthly protection money to always come up near the top in the company name searches. |
if Liontrust are distressed sellers then we need to wait until they have cleared out their sale orders - is this now the case? |
My guess would simply be the budget Dom. |
If they wanted it down,and back to where it was languishing a fortnight ago, what was the breakout through £4 for? |
I'm pretty confident that OXB have at least one "proper" RNS locked and loaded. |
Yes indeed but i think its very easy for companies to concentrate on the job in hand,especially when they're involved in an esoteric science like biotech.A lot of senior management don't give two figs for the stock exchange and don't have much confidence that some teenage scribbler will fully understand their business.They probably have a point.Ultimately,the proof of the pudding will be in the eating and the reality will out.Looking at the way the Oxford Biomedica share price has moved over the last three years,you could be forgiven for believing the stock exchange is a complete lottery.I have long felt that numerous smaller companies would be better off staying private.That said,i agree,if you are listed you should make every effort to communicate your corporate message effectively. |
Steeplejack. Isn't that an argument to support companies, especially smaller companies, to use their own publicity departments to promote the company? |
I agree Dom. |
You know me well Mr President Sir, but the issue is ANY attempt to promote the share value is absent other than relying on two occasions in the year, Interims and Results. Not good enough these days. |
takeiteasy, |
Dom, |
hxxps://www.closebro |
#9036 Nor have we released any market sensitive news. Perhaps there is no equivalent to 'RNS' in French? |
Only if there are enormous funds out there which are either techmark LSE index trackers or have fund rules which include techmark LSE index constituents as an option. |
Harry, we have never left the techmark LSE index - has that helped though? :) |
With the budget / budget management campaign (pre-budget leaks of much worse) now over, I think the 3 points listed below will determine whether the new year's eve party (2 months tonight) is M&S best ever sausage rolls or Tesco value. |
In their previous sales to meet fund redemptions there has often been a news release saying that they have sold the same tiny percentage of everything they hold. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 415.00 |
Offer Price | 418.50 |
Open | 413.00 |
Shares Traded | 157,836 |
Last Trade | 16:35:13 |
Low - High | 410.50 - 426.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7380 |
PE Ratio | -2.41 |
Market Cap | 437.62M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads